{"title":"Synthesis of 4-Azaindole-Thiazolidine-2,4-Dione Coupled 1,2,3-Triazoles as EGFR Directing Anticancer Agents","authors":"","doi":"10.1080/10406638.2023.2259563","DOIUrl":null,"url":null,"abstract":"<div><div>Herein, we synthesized some new 4-azaindole-thiazolidine-2,4-dione-1,2,3-triazole hybrids (<strong>6a-6n</strong>) <em>via</em> Knoevenagel condensation and copper(I) catalyzed azide-alkyne cycloaddition (CuAAC) as key approaches. These hybrids were then screened for their <em>in vitro</em> anticancer activity against three human cancer cell lines like MCF-7 (breast), A549 (lung) and HepG2 (hepatocellular) using erlotinib as standard drug. Out of all, compounds <strong>6a</strong>, <strong>6k</strong> and <strong>6m</strong> were found to be more active against all cell lines with IC<sub>50</sub> values <18 µM. As well, compounds <strong>6a</strong> (IC<sub>50</sub> = 0.40 µΜ), <strong>6k</strong> (IC<sub>50</sub> = 0.29 µΜ) and <strong>6m</strong> (IC<sub>50</sub> = 0.18 µΜ) showed higher potency ininhibiting tyrosine kinase EGFR than the erlotinib (IC<sub>50</sub> = 0.41 µΜ). Further, molecular dockingof compounds <strong>6a</strong>, <strong>6k</strong> and <strong>6 m</strong> on EGFR protein revealed that they have good binding energies with the target protein (−9.96 kcal/mol, −9.92 kcal/mol and −10.37 kcal/mol respectively) which were found to be supportive with the corresponding <em>in vitro</em> activities data.</div></div>","PeriodicalId":20303,"journal":{"name":"Polycyclic Aromatic Compounds","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Polycyclic Aromatic Compounds","FirstCategoryId":"92","ListUrlMain":"https://www.sciencedirect.com/org/science/article/pii/S1040663823020286","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, ORGANIC","Score":null,"Total":0}
引用次数: 0
Abstract
Herein, we synthesized some new 4-azaindole-thiazolidine-2,4-dione-1,2,3-triazole hybrids (6a-6n) via Knoevenagel condensation and copper(I) catalyzed azide-alkyne cycloaddition (CuAAC) as key approaches. These hybrids were then screened for their in vitro anticancer activity against three human cancer cell lines like MCF-7 (breast), A549 (lung) and HepG2 (hepatocellular) using erlotinib as standard drug. Out of all, compounds 6a, 6k and 6m were found to be more active against all cell lines with IC50 values <18 µM. As well, compounds 6a (IC50 = 0.40 µΜ), 6k (IC50 = 0.29 µΜ) and 6m (IC50 = 0.18 µΜ) showed higher potency ininhibiting tyrosine kinase EGFR than the erlotinib (IC50 = 0.41 µΜ). Further, molecular dockingof compounds 6a, 6k and 6 m on EGFR protein revealed that they have good binding energies with the target protein (−9.96 kcal/mol, −9.92 kcal/mol and −10.37 kcal/mol respectively) which were found to be supportive with the corresponding in vitro activities data.
期刊介绍:
The purpose of Polycyclic Aromatic Compounds is to provide an international and interdisciplinary forum for all aspects of research related to polycyclic aromatic compounds (PAC). Topics range from fundamental research in chemistry (including synthetic and theoretical chemistry) and physics (including astrophysics), as well as thermodynamics, spectroscopy, analytical methods, and biology to applied studies in environmental science, biochemistry, toxicology, and industry. Polycyclic Aromatic Compounds has an outstanding Editorial Board and offers a rapid and efficient peer review process, as well as a flexible open access policy.